Navigation Links
Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration
Date:7/24/2014

OVERLAND PARK, Kan., July 24, 2014 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd announces the successful licensing of two compounds that will be added to Parnell's already extensive pipeline through a license agreement with Australian-based CIMTECH Pty Ltd, a biotechnology company. The compounds now known as PAR 121 and PAR 122 have shown promise in bone regeneration and dermal regeneration, respectively. Parnell has received a license to develop the compounds for the veterinary market with the potential to also seek human drug approvals.

"We are excited to have completed this deal with CIMTECH which we feel supports our proposition that we can quickly and efficiently develop veterinary drugs due to our demonstrated competencies across the entire pharmaceutical value chain," says Robert Joseph, President and CEO. "This deal is consistent with our vision to discover, develop and deliver the best animal health solutions, and we look forward to many more licensing deals in the future."

Prior to licensing the compounds to Parnell, CIMTECH had undertaken pre-clinical studies for PAR121 that demonstrated a rapid formation of bone matrix in a rabbit ulna critical defect model. Compared to control subjects that did not heal, PAR121-treated subjects achieved new bone in-growth in just one week, and in bone grafting achieved new bone growth and remodeling in 6 weeks that would typically take 12 weeks. If Parnell is successful in developing PAR121 into a marketable drug, the financial implications could be significant; in the USA each year, over $1.5 billion is spent on canine knee surgeries alone. The ability to utilize a product that rapidly improves the speed of bone healing could be very significant.

Pre-clinical studies into PAR122 showed similarly impressive outcomes with a rapid and significant thickening of the epidermis in treated subjects and an improvement in acute wound healing. A drug developed with the PAR122 compound could be used to rapidly repair skin and therefore may be useful in treating conditions such as atopic dermatitis, a very common condition in dogs, typically caused by flea allergy.

CEO & President Robert Joseph said that if successfully developed, both compounds may become blockbuster products given there is nothing else like them in the veterinary market. They could also potentially be developed for human use.

The licenses is perpetual and exclusive and provides Parnell worldwide rights to market any resulting veterinary and/or human drugs as well as a right to sub-license to third parties. In order to retain the licence Parnell must continue to undertake development of the compounds each year and will bear all costs of; drug development, intellectual property, drug approvals and commercialization. Parnell will pay $100,000 as an upfront payment to CIMTECH and up to a further $1.9 million in milestone payments plus a single digit royalty on all Net Revenues received by Parnell from all drug sales (veterinary and human).

About Parnell

Parnell (NASDAQ: PARN) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms - iKAM and mySYNCH. These innovative technology solutions are designed to enhance the quality of life or performance of animals, while driving customers' operational efficiency and profitability. Parnell believes its value-added solutions help establish them as a business partner with customers rather than only as a commodity provider, differentiating them from competitors.

For more information on the Company and its products, please visit www.parnell.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "develops," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject to a number of risk and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell's research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell's Form F-1 Registration Statement effective June 18, 2014. In light of these assumptions, risks, and uncertainties, the results and events discussed in the forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

Photo - http://photos.prnewswire.com/prnh/20140724/130313


'/>"/>
SOURCE Parnell Pharmaceuticals Holdings
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
2. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
3. PLZ Aeroscience Acquires Assured Packaging
4. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
5. PneumRx, Inc. Acquires Key Assets From Broncus
6. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
7. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
8. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
9. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
10. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
11. AstraZeneca Acquires Neuroscience Assets From Link Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):